Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) insider Khurram Jamil sold 4,570 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $5.00, for a total transaction of $22,850.00. Following the completion of the sale, the insider owned 2,037 shares of the company’s stock, valued at approximately $10,185. The trade was a 69.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Khurram Jamil also recently made the following trade(s):
- On Monday, June 29th, Khurram Jamil sold 47,467 shares of Galectin Therapeutics stock. The stock was sold at an average price of $5.04, for a total transaction of $239,233.68.
- On Tuesday, June 23rd, Khurram Jamil sold 7,557 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.14, for a total transaction of $23,728.98.
- On Tuesday, May 26th, Khurram Jamil sold 568 shares of Galectin Therapeutics stock. The shares were sold at an average price of $3.10, for a total transaction of $1,760.80.
Galectin Therapeutics Stock Down 6.6%
Shares of NASDAQ GALT traded down $0.33 during trading on Tuesday, hitting $4.64. 1,122,352 shares of the company traded hands, compared to its average volume of 992,716. Galectin Therapeutics Inc. has a 1 year low of $2.03 and a 1 year high of $7.13. The company has a 50-day moving average price of $2.65 and a 200-day moving average price of $3.06. The firm has a market capitalization of $305.59 million, a P/E ratio of -11.32 and a beta of 0.47.
Wall Street Analysts Forecast Growth
GALT has been the topic of a number of research reports. Weiss Ratings upgraded Galectin Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Galectin Therapeutics in a report on Tuesday, June 23rd. Finally, Wall Street Zen raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Galectin Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $11.00.
Check Out Our Latest Research Report on Galectin Therapeutics
Hedge Funds Weigh In On Galectin Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its holdings in Galectin Therapeutics by 25.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,470 shares of the company’s stock valued at $66,000 after purchasing an additional 3,133 shares in the last quarter. Royal Bank of Canada lifted its holdings in Galectin Therapeutics by 1,197.3% in the 4th quarter. Royal Bank of Canada now owns 6,175 shares of the company’s stock worth $25,000 after buying an additional 5,699 shares in the last quarter. Invesco Ltd. acquired a new position in Galectin Therapeutics in the 4th quarter worth $43,000. State Street Corp boosted its position in Galectin Therapeutics by 5.2% in the 4th quarter. State Street Corp now owns 242,232 shares of the company’s stock valued at $1,008,000 after buying an additional 11,892 shares during the last quarter. Finally, Cetera Investment Advisers purchased a new position in Galectin Therapeutics in the 4th quarter valued at about $59,000. Hedge funds and other institutional investors own 11.68% of the company’s stock.
Galectin Therapeutics Company Profile
Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.
Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.
Read More
- Five stocks we like better than Galectin Therapeutics
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
